CVS HEALTH Corp 8-K

What Happened
CVS Health (CVS) filed an 8-K (Item 5.02) reporting that on March 18, 2026 its Board elected John E. Gallina, age 66, to serve as a director effective March 19, 2026. Mr. Gallina is the former Executive Vice President and Chief Financial Officer of Elevance Health, Inc., serving as CFO from June 2016 through November 1, 2023, and as EVP and Advisor to the CEO through May 2024 before retiring.

Key Details

• Election effective March 19, 2026; disclosed in an 8-K filed March 19, 2026.
• Mr. Gallina, age 66, served as Elevance CFO June 2016–Nov 1, 2023; then EVP and Advisor to the CEO until May 2024.
• Previously held finance and audit roles at Elevance (including Chief Accounting Officer and Chief Risk Officer) and was a senior audit manager/CPA at Coopers & Lybrand.
• Currently a director of Arrive AI, Inc. (Nasdaq: ARAI) and chairs its audit committee; serves on boards of private non-profits.
• Board determined Mr. Gallina is “independent” under NYSE and CVS guidelines; he was appointed to CVS’s Audit Committee and designated an “audit committee financial expert.”
• Director pay will follow CVS’s standard non-employee director compensation, prorated for his start date (as described in CVS’s 2025 proxy).

Why It Matters
This is a governance and oversight change: CVS added a director with recent, senior financial and audit experience at a large health benefits company and audit committee leadership experience. For investors, his independence, audit committee role and designation as an audit committee financial expert may strengthen financial oversight and reporting controls. The filing does not report changes to executive officers or material financial terms beyond standard director compensation.